Pfizer announced topline results from the Phase 3 trial (ATTR-ACT) of tafamidis for the treatment of transthyretin cardiomyopathy. The results showed that the primary endpoint was met as evident by a statistically significant reduction in the combination of all-cause mortality and incidence of cardiovascular-related hospitalizations with tafamidis vs placebo.
A total of 441 patients were enrolled in the multicenter, double-blind, placebo-controlled, randomized ATTR-ACT study; both variant (hereditary) and wild-type form (non-hereditary) form of transthyretin cardiomyopathy were included in the study. Patients were required to have amyloid deposits in biopsy tissue and a variant TTR genotype and/or TTR precursor protein identification by immunohistochemistry, scintigraphy or mass spectrometry.
Patients were randomized into 1 of 3 arms: daily tafamidis meglumine 20mg or 80mg capsules, or placebo. The primary outcome was all-cause mortality and frequency of cardiovascular-related hospitalization, from baseline to Month 30.
Although the preliminary data are subject to further analysis, study authors observed a statistically significant reduction in the combination of all-cause mortality and frequency of cardiovascular-related hospitalizations compared to placebo at 30 months. Additionally, safety data showed that tafamidis was generally well-tolerated with no new safety signals.
Transthyretin cardiomyopathy is a rare and underdiagnosed condition with no approved treatments. Tafamidis was previously granted Fast Track designation for transthyretin cardiomyopathy in 2017. Full ATTR-actresults will be submitted for presentation at an upcoming scientific conference and for peer-review publication.
For more information visit Pfizer.com.
This article originally appeared on MPR